Engaging Innovation | Friends of Cancer Research

Engaging Innovation

Featured Post

October 10, 2019

Despite criticism, FDA is doing what is right by rare cancer patients

On October 1, the first-ever Rare Cancer Day, an awareness day highlighting the challenges people living with rare cancers face and emphasizing the importance of early diagnosis, was marked by thousands nationwide. Cancer is not a singular disease but, rather, many diseases, of which several are rare. One in 5...
More Posts

Recent Posts

No Results With Current Filter Choices

8th Blueprint for Breakthrough: Validating Real-World Endpoints for an Evolving Regulatory Landscape

  "Real-World Evidence is already here." - Ned Sharpless, Acting FDA Commissioner On September 18, 2019, Friends of Cancer Research (Friends) and Alexandria Real Estate Equities, Inc. hosted a meeting to present data from the Real-World Evidence (RWE) Pilot 2.0, building on the Friends RWE Pilot 1.0. The meeting focused on the...

Real-World Evidence Roundtable

Friends of Cancer Research (Friends) convened a roundtable meeting on February 6, 2019, to identify key challenges and next steps to further characterize how real-world evidence (RWE) can fill evidence gaps about the performance of approved agents used in the real-world setting, including in populations that may not have been...

Designing the Future of Cell Therapies

“Patients are waiting. These therapies are potentially curative. They’re important for the field.” - Ellen Sigal   On May 17, 2019, Friends of Cancer Research (Friends) and the Parker Institute for Cancer Immunotherapy (PICI) held a public meeting on “Designing the Future of Cell Therapies” to explore forward-looking opportunities in the cell...

Data Driven: How Oncologists Perceive FDA-Approved Drug Labeling Compared to Other Major Prescribing Resources

Physicians rely on a variety of sources of information to provide high-quality care to patients. In oncology, some of the most prominent resources that inform provider decision-making are the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) clinical practice guidelines; drug compendia; electronic point-of-care decision...

TMB Harmonization Working Group Fall Meeting

On September 13, 2018, Friends of Cancer Research (Friends) reconvened the TMB Harmonization Working Group, which consists of several stakeholders across all health sectors. Building from previous workshops hosted by Friends in the Fall of 2017 and the Spring of 2018, working group members:   Reviewed the findings of the first phase...

A Blueprint for Breakthrough: Research and Reimbursement in the Age of Precision Medicine

  Next-generation sequencing (NGS) is becoming a commonly used tool in cancer treatment. Transparency regarding the clinical performance and utility of different NGS-based tests available will aid in clinical decision-making and facilitate improvements in patient care.  The 7th Annual Blueprint for Breakthrough Forum, held by Friends of Cancer Research (Friends) and...

The FDA’s Budget: How Government Funds Safety and Efficacy

The U.S. Food and Drug Administration (FDA) fulfills its mission to protect and advance the public health by overseeing the development and approval of new medical products and ensuring that they are safe and effective for American consumers. When taking into consideration the full range of products the FDA oversees,...
first
prev
1
2
3
4
next
last
Back to Top